NCT06337474View on ClinicalTrials.gov

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2026

Conditions
Thrombocytopenia Alloimmune
Interventions
DRUG

anti-CD19 CAR NK cells (KN5501)

Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3. Doses of 9×10\^9 cells, 13.5×10\^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the dose-escalation strategy

Trial Locations (1)

213000

RECRUITING

Changzhou Second People's Hospital, Changzhou

All Listed Sponsors
collaborator

Rui Therapeutics Co., Ltd

INDUSTRY

lead

Changzhou No.2 People's Hospital

OTHER